{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T21:05:33Z","timestamp":1788210333951,"version":"build-2803163510"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Orthotopic liver transplantation (OLT), as one of the curative methods for the treatment of hepatocellular carcinoma (HCC), has brought hope to patients with HCC. However, treatment options for HCC recurrence and metastasis after liver transplantation are limited. Immune checkpoint inhibitor (ICI), such as programmed cell death protein 1 (PD-1) inhibitor, have been successfully used in advanced or metastatic HCC, but the data on the safety of PD-1 inhibitor after liver transplantation is limited. In this article, we report a 47-year-old patient with acute-on-chronic liver failure and multiple HCC who was successfully treated with liver transplantation. On the 45th day after OLT, the patient\u2019s alpha fetoprotein\u00a0(AFP) and lens culinaris agglutinin-reactive fraction of AFP (AFP-L3) were increased, and imaging examination showed no residual tumor. The patient had high risk factors for tumor recurrence before operation, so the possibility of tumor recurrence was considered. When the tumor markers showed an upward trend, we immediately treated the patient with lenvatinib 8 mg, after half a month, the AFP and AFP-L3 continued to increase compared with before. Then we used low-dose nivolumab 40mg, the patient\u2019s AFP and AFP-L3 gradually decreased. One month later, a second low-dose nivolumab 40mg was given, and the patient\u2019s tumor markers gradually decreased to normal. No acute rejection and other complications occurred during the treatment. So far, we have followed up this patient for 2 years, and no tumor recurrence was observed.\u00a0To our knowledge, this is the first reported case using a low dose of nivolumab in combination with lenvatinib to prevent recurrence of HCC after liver transplantation.<\/jats:p>","DOI":"10.3389\/fonc.2022.951303","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T08:15:42Z","timestamp":1662106542000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":10,"title":["Low-dose PD-1 inhibitor combined with lenvatinib for preemptive treatment of recurrence after liver transplantation for hepatocellular carcinoma: Case report and literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Xin","family":"Jin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kangjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taishi","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinchen","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianxin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziming","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linjie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2014-308513","article-title":"Liver transplantation for hepatocellular carcinoma beyond the Milan criteria","volume":"65","author":"Xu","year":"2016","journal-title":"Gut"},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/S1470-2045(08)70284-5","article-title":"Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: A retrospective, exploratory analysis","volume":"10","author":"Mazzaferro","year":"2009","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.24563","article-title":"Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival","volume":"33","author":"Yao","year":"2001","journal-title":"Hepatology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2016.193","article-title":"Liver transplantation for hepatocellular carcinoma: outcomes and novel surgical approaches","volume":"14","author":"Sapisochin","year":"2017","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20039","article-title":"Underestimation of the influence of satellite nodules as a risk factor for post-transplantation recurrence in patients with small hepatocellular carcinoma","volume":"10","author":"Plessier","year":"2004","journal-title":"Liver Transpl"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28643","article-title":"The extended Toronto criteria for liver transplantation in patients with hepatocellular carcinoma: A prospective validation study","volume":"64","author":"Sapisochin","year":"2016","journal-title":"Hepatology"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.trre.2016.03.001","article-title":"Serologic and molecular biomarkers for recurrence of hepatocellular carcinoma after liver transplantation: A systematic review and meta-analysis","volume":"30","author":"Pommergaard","year":"2016","journal-title":"Transplant Rev (Orlando)"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2007.06.042","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation","volume":"39","author":"Escartin","year":"2007","journal-title":"Transplant Proc"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1111\/ajt.15697","article-title":"Liver transplantation for hepatocellular carcinoma: Management after the transplant","volume":"20","author":"Verna","year":"2020","journal-title":"Am J Transpl"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2174\/1568009620666200520084415","article-title":"Immune checkpoint inhibitors in patients with recurrent hepatocellular carcinoma after liver transplantation: A case report and literature review","volume":"20","author":"Qiu","year":"2020","journal-title":"Curr Cancer Drug Targets"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1097\/TXD.0000000000000814","article-title":"Liver allograft failure after nivolumab treatment-a case report with systematic literature research","volume":"4","author":"Gassmann","year":"2018","journal-title":"Transplant Direct"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.387","article-title":"Preserved liver transplant after PD-1 pathway inhibitor for hepatocellular carcinoma","volume":"112","author":"Varkaris","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26682","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma","volume":"64","author":"Friend","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29575","article-title":"Pembrolizumab for metastatic hepatocellular carcinoma following live donor liver transplantation: The silver bullet","volume":"67","author":"Rammohan","year":"2018","journal-title":"Hepatology"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2019.11.009","article-title":"Successful treatment of disseminated hepatocellular carcinoma after liver transplantation with nivolumab","volume":"10","author":"Amjad","year":"2020","journal-title":"J Clin Exp Hepatol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.01.063","article-title":"Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient","volume":"152","author":"De Toni","year":"2017","journal-title":"Gastroenterology"},{"key":"B18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s40425-016-0177-2","article-title":"Nivolumab dose selection: Challenges, opportunities, and lessons learned for cancer immunotherapy","volume":"4","author":"Agrawal","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1373\/clinchem.2019.308965","article-title":"A novel online calculator based on serum biomarkers to detect hepatocellular carcinoma among patients with hepatitis b","volume":"65","author":"Yang","year":"2019","journal-title":"Clin Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24742","article-title":"Recurrence of hepatocellular carcinoma after liver transplantation: Is there a place for resection","volume":"23","author":"Fernandez-Sevilla","year":"2017","journal-title":"Liver Transpl"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2018.12.029","article-title":"Live donor liver transplantation for patients with hepatocellular carcinoma offers increased survival vs","volume":"70","author":"Goldaracena","year":"2019","journal-title":"deceased donation. J Hepatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/17474124.2018.1417035","article-title":"Liver transplantation beyond or downstaging within the Milan criteria for hepatocellular carcinoma","volume":"12","author":"Rudnick","year":"2018","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1177\/2050640619840221","article-title":"Long-term observation of hepatocellular carcinoma recurrence after liver transplantation at a European transplantation centre","volume":"7","author":"Foerster","year":"2019","journal-title":"U Eur Gastroenterol J"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2017.06.007","article-title":"Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features","volume":"153","author":"Sia","year":"2017","journal-title":"Gastroenterology"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27246","article-title":"Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions","volume":"60","author":"Hato","year":"2014","journal-title":"Hepatology"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.7150\/thno.28742","article-title":"Clinical significance of PD-1\/PD-Ls gene amplification and overexpression in patients with hepatocellular carcinoma","volume":"8","author":"Ma","year":"2018","journal-title":"Theranostics"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28710","article-title":"Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship with clinical and pathological features","volume":"64","author":"Calderaro","year":"2016","journal-title":"Hepatology"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30011-5","article-title":"Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial","volume":"21","author":"Qin","year":"2020","journal-title":"Lancet Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802357","article-title":"Adjuvant pembrolizumab versus placebo in resected stage III melanoma","volume":"378","author":"Eggermont","year":"2018","journal-title":"N Engl J Med"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"El-Khoueiry","year":"2017","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/S1470-2045(21)00604-5","article-title":"Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial","volume":"23","author":"Yau","year":"2022","journal-title":"Lancet Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6","article-title":"Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial","volume":"19","author":"Zhu","year":"2018","journal-title":"Lancet Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1159\/000505695","article-title":"Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma","volume":"9","author":"Deng","year":"2020","journal-title":"Liver Cancer"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0212513","article-title":"Lenvatinib plus anti-PD-1 antibody combination treatment activates CD8+ T cells through reduction of tumor-associated macrophage and activation of the interferon pathway","volume":"14","author":"Kato","year":"2019","journal-title":"PLoS One"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31921","article-title":"Lenvatinib targets FGF receptor 4 to enhance antitumor immune response of anti-programmed cell death-1 in HCC","volume":"74","author":"Yi","year":"2021","journal-title":"Hepatology"},{"key":"B37","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s12885-022-09405-7","article-title":"Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications","volume":"22","author":"Sun","year":"2022","journal-title":"BMC Cancer"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01248-0","article-title":"Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience","volume":"40","author":"Wu","year":"2022","journal-title":"Invest New Drugs"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1758835919843463","DOI":"10.1177\/1758835919843463","article-title":"Harnessing immunotherapy for liver recipients with hepatocellular carcinoma: a review from a transplant oncology perspective","volume":"11","author":"Ho","year":"2019","journal-title":"Ther Adv Med Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2014.05.006","article-title":"The PD-1\/PD-Ls pathway and autoimmune diseases","volume":"290","author":"Dai","year":"2014","journal-title":"Cell Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00467","article-title":"PD-1-Mediated PI3K\/Akt\/mTOR, caspase 9\/Caspase 3 and ERK pathways are involved in regulating the apoptosis and proliferation of CD4+ and CD8+ T cells during BVDV infection in vitro","volume":"11","author":"Liu","year":"2020","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.8.5204","article-title":"PDL1 is required for peripheral transplantation tolerance and protection from chronic allograft rejection","volume":"179","author":"Tanaka","year":"2007","journal-title":"J Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000180","article-title":"Immune checkpoint inhibitors in organ transplant patients","volume":"40","author":"Kittai","year":"2017","journal-title":"J Immunother"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.11150","article-title":"Anti-programmed cell death protein 1 (PD-1) immunotherapy for metastatic hepatocellular carcinoma after liver transplantation: A report of three cases","volume":"12","author":"Al Jarroudi","year":"2020","journal-title":"Cureus"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.07.05","article-title":"Pilot evaluation of PD-1 inhibition in metastatic cancer patients with a history of liver transplantation: The Mayo clinic experience","volume":"9","author":"DeLeon","year":"2018","journal-title":"J Gastrointest Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.04.012","article-title":"T Cell cosignaling molecules in transplantation","volume":"44","author":"Ford","year":"2016","journal-title":"Immunity"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1177\/2050640618774631","article-title":"Use of checkpoint inhibitors in liver transplant recipients","volume":"6","author":"Munker","year":"2018","journal-title":"U Eur Gastroenterol J"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1136\/esmoopen-2018-000332","article-title":"Low-dose nivolumab can be effective in non-small cell lung cancer: alternative option for financial toxicity","volume":"3","author":"Yoo","year":"2018","journal-title":"ESMO Open"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.951303\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T08:15:45Z","timestamp":1662106545000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.951303\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,2]]},"references-count":48,"alternative-id":["10.3389\/fonc.2022.951303"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.951303","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,2]]},"article-number":"951303"}}